Only FDA-Approved* Disease Modifying Osteoarthritis Drug (DMOAD)
Adequan® Canine (polysulfated glycosaminoglycan) is the only FDA-approved* DMOAD for dogs in the U.S.

Polysulfated vs. Monosulfated
Adequan® Canine contains multiple sulfur molecules. The larger number of sulfur molecules helps to inhibit the various enzymes that lead to cartilage destruction in arthritis and enhances cartilage metabolism.

Different Active
Adequan® Canine delivers therapeutic drug levels to synovial joints by avoiding the digestive enzymes of the GI tract.

Smallest Molecule
Adequan® Canine’s low molecular weight means it can’t be blocked from the synovial fluid by the synovial membrane.

Proven Efficacy
Several studies** have demonstrated the efficacy of Adequan® Canine in controlling signs of non-infectious degenerative and/or traumatic arthritis.
 

* NADA #141-038, Approved by FDA
** Source: Freedom of Information - NADA #141-038; Title: Controlled Field Trial